NCT03977337

Brief Summary

  1. 1.Describe the incidence of postoperative hypoxemia after major emergency abdominal surgery as well as correlate this to clinical outcomes.
  2. 2.Investigate the association between postoperative pulmonary complications and respiratory muscle dysfunction.
  3. 3.Investigate the association between the length and type of incision as well as the distance to the xiphoid process and respiratory muscle dysfunction.
  4. 4.Investigate the association between postoperative hypoxemia, myocardial ischemia and ischemic electrocardiographic (ECG) changes within three days of major emergency abdominal surgery
  5. 5.Describe the incidence of postoperative cardiac arrhythmias within three days of major emergency abdominal surgery and the association with postoperative cardiovascular complications within 30 days, 90 days and 1 year of surgery.
  6. 6.Describe the association between HRV and postoperative cardiovascular and non-cardiovascular complications within 30 days, 90 days and 1 year of surgery

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
350

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 29, 2018

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 14, 2019

Completed
5 months until next milestone

First Posted

Study publicly available on registry

June 6, 2019

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2019

Completed
Last Updated

June 6, 2019

Status Verified

June 1, 2019

Enrollment Period

1 year

First QC Date

January 14, 2019

Last Update Submit

June 4, 2019

Conditions

Outcome Measures

Primary Outcomes (7)

  • Change in postoperative maximal inspiratory mouth pressure from POD1 to POD3

    Maximal inspiratory mouth pressure \[cmH2O\] is measured on the first and third postoperative day to asses the change

    3 days

  • Change in postoperative maximal expiratory mouth pressure from POD1 to POD3

    Maximal expiratory mouth pressure \[cmH2O\] is measured on the first and third postoperative day to asses the change

    3 days

  • Length of surgical incision

    The length of the surgical incision \[cm\] will be measured on the first postoperative day

    Day 1

  • Heart Rate Variability (HRV)

    HRV assessed preoperatively - POD3, if this is not achievable then from POD0 - POD3

    3 days

  • The occurence of per- and postoperative cardiac arrhythmias (until POD3)

    The occurence of postoperative cardiac arrhythmia the first three days following surgery, with cardiac arrhythmia defined as: * Atrial fibrillation (AF) or * Atrial Flutter (AFL) or * Ventricular Tachycardia (VT- both monomorphic and polymorphic types) or * Recurrent sustained ventricular tachycardia (RSVT) or * Ventricular fibrillation (VF) or * Torsade de Pointes (TDP) or * 2nd degree atrioventricular (AV) block or * 3rd degree atrioventricular (AV) block

    3 days

  • The occurence of per- and postoperative ischemic ECG changes (until POD3)

    The occurence of per- and postoperative ischemic ECG changes the first three days following surgery, defined as: * ST-depression ≥ 0,5 mm at the J-point in ≥ 2 contiguous leads or * Inverted T waves ≥ 1 mm in ≥2 contiguous leads that have dominant R waves or * ST-elevation ≥ 1 mm in ≥ 2 contiguous leads, however * ST-elevation in V2-V3 ≥ 2,5 mm for males \< 40 years of age in ≥ 2 contiguous leads * ST-elevation in V2-V3 ≥ 2,0 mm for males ≥ 40 years of age in ≥ 2 contiguous leads * ST-elevation in V2-V3 ≥ 1,5 mm for females in ≥ 2 contiguous leads) or * In V2-V3: Any q wave ≥ 0,02 seconds, * In other leads: Q wave ≥ 0,03 seconds and \> 1 mm deep in ≥ 2 contiguous leads.

    3 days

  • The occurence of postoperative hypoxemia during the first three postoperative days

    The occurence of postoperative hypoxemia during the first three postoperative days, defined as: * the number of declines in saturation of 4 % (or more) lasting 20 seconds (or more) or * number of desaturation episodes below 90 % or * time (minutes( spent below 90 %,

    3 days

Interventions

Major emergency gastrointestinal surgery performed within 72 hours of an acute admission or an acute reoperation.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients admitted to the department of Surgery, Zealand University Hospital, Denmark.

You may qualify if:

  • Surgery within 72 hours of an acute admission to the Department of Surgery or an acute reoperation.
  • Major gastrointestinal surgery on the gastrointestinal tract.
  • This will include:
  • Open, laparoscopic, or laparoscopically-assisted procedures
  • Procedures involving the stomach, small or large bowel, or rectum for conditions such as perforation, ischemia, abdominal abscess, bleeding or obstruction
  • Washout/evacuation of intra-peritoneal abscess (unless due to appendicitis or cholecystitis - excluded, see below)
  • Washout/evacuation of intra-peritoneal hematoma
  • Bowel resection/repair due to incarcerated umbilical, inguinal and femoral hernias (but not hernia repair without bowel resection/repair)
  • Bowel resection/repair due to obstructing/incarcerated incisional hernias provided the presentation and findings were acute
  • Laparotomy/laparoscopy with inoperable pathology (e.g. peritoneal/hepatic metastases)
  • Laparoscopic/Open adhesiolysis
  • Return to theatre for repair of fascial dehiscence
  • Any reoperation/return to theatre meeting the criteria above is included
  • If multiple procedures (primary surgery or reoperation) are performed on different anatomical sites within the abdominal/pelvic cavity, the patient would be included if the major procedure is general surgical.

You may not qualify if:

  • Not capable of giving informed consent after oral and written information
  • Previously included in the trial
  • Elective laparoscopy
  • Diagnostic laparotomy/laparoscopy where no subsequent procedure is performed (NB, if no procedure is performed because of inoperable pathology, then include)
  • Appendectomy +/- drainage of localized collection unless the procedure is incidental to a non-elective procedure on the GI tract
  • Cholecystectomy +/- drainage of localized collection unless the procedure is incidental to a non-elective procedure on the GI tract (All surgery involving the appendix or gallbladder, including any surgery relating to complications such as abscess or bile leak is excluded)
  • Non-elective hernia repair without bowel resection.
  • Minor abdominal wound dehiscence unless this causes bowel complications requiring resection
  • Ruptured ectopic pregnancy, or pelvic abscesses due to pelvic inflammatory disease
  • Laparotomy/laparoscopy for pathology caused by blunt or penetrating trauma
  • Laparotomy/laparoscopy for esophageal pathology
  • Laparotomy/laparoscopy for pathology of the spleen, renal tract, kidneys, liver, gall bladder and biliary tree, pancreas or urinary tract

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Surgery, Zealand University Hospital, Denmark.

Køge, 4600, Denmark

RECRUITING

MeSH Terms

Conditions

Postoperative Complications

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Ismail Gögenur, MD

    Zealand University Hospital

    STUDY CHAIR
  • Jakob Burcharth, MD

    Zealand University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ismail Gögenur, MD

CONTACT

Jakob Burcharth, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 14, 2019

First Posted

June 6, 2019

Study Start

November 29, 2018

Primary Completion

November 30, 2019

Study Completion

November 30, 2019

Last Updated

June 6, 2019

Record last verified: 2019-06

Locations